Optical genome mapping detects additional genetic variants in nearly 20% of individuals with acute leukemia

New research assessing the efficacy of optical genome mapping (OGM) in a group of patients with acute leukemia has demonstrated that OGM provided reliable and robust analytical performance with high sensitivity and specificity in detecting genetic alterations. In nearly 20% of cases, additional genetic variants were found that standard tests had missed. Although these current standard assays retain value in the diagnostic workflow, the study, published in The Journal of Molecular Diagnostics, shows that OGM offers an exceptional complement and can replace certain elements of the current testing algorithm.